Novo Nordisk has introduced oral versions of its popular weight-loss drugs Ozempic and Wegovy, now available for same-day delivery on Amazon. These once-daily pills follow the original weekly injectables and have quickly gained over one million users since launch. CEO Mike Doustdar highlighted the broader health benefits beyond weight loss and emphasized efforts to keep prices fair for wider patient access. The company is also developing a promising new drug for liver disease that could reduce the need for transplants.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
